跳至主要内容
临床试验/NCT00803894
NCT00803894已完成1 期

A Randomized Clinical Trial to Study the Effects of MK0752 Versus Placebo on Biomarkers in Healthy Young Adult Male Subjects

Merck Sharp & Dohme LLC0 个研究点目标入组 30 人开始时间: 2008年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
30
主要终点
To evaluate the existing Notch response signature using plucked hair follicle profiling data from health young male volunteers given 1000 mg MK0752 and 350 mg MK0752.

研究概览

简要总结

The purpose of this study is to determine the transcriptional signature of Notch Inhibition by testing hair and blood samples on healthy male volunteers who have received MK0752 vs placebo for possible future biomarkers in the treatment of cancer or Alzheimers Disease

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Patient is a male
  • Patient has no clinically significant abnormality on electrocardiogram performed
  • Patient agrees to not to consume apple juice, grapefruit or grapefruit products beginning 2 weeks prior to first dose of study drug and for the duration of the study
  • Patient has been a nonsmoker and/or has not used nicotine or nicotine-containing products for approximately 6 months.
  • Patient is willing to not use any hair enhancement product or procedures for the duration of the study (for example, permanents, hair straightening techniques)
  • Patient has a full head of hair
  • Patient has at least 90% non-gray hair

排除标准

  • Patient has had treatment with any investigational therapy during the prior 21 days
  • Patient has any history of significant gastrointestinal abnormalities within the last 10 years
  • Patient has a history of any long-term or active liver disease including elevated liver blood tests. Any patient with a history of Hepatitis B or C (and/or treated previously) will be excluded
  • Patient has a known history or family history of aortic valve disease, congenital (from birth) heart disease or deafness, hearing loss or early onset Alzheimer's disease (onset at age < 55)
  • Patient has a known sensitivity to the ingredients in the drug
  • Patient has had active and uncontrolled infection within the past month
  • Patient is HIV positive
  • Patient has a history of stomach, intestine, heart, blood, liver, brain, kidney, lung, bladder or endocrine abnormalities or diseases
  • Patient has a history of cancer except for certain skin cancer (basal cell)
  • Patient has a history of multiple and/or severe allergies or has had an allergic reaction to food or prescription/non-prescription drugs
  • Patient has had major surgery, donated or lost 1 unit of blood (about 500 mL) within the past month
  • Patient has premature graying hair (> 10% gray hair)
  • Patient has male pattern hair loss
  • Patient has a prior history of high blood pressure
  • Patient uses any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort) beginning approximately 2 weeks prior to the first dose of study drug, throughout the study until the post study visit
  • Patient consumes excessive amounts of alcohol (greater than 3 glasses of alcoholic beverages)
  • Patient consumes excessive amounts (greater than 6 servings) of coffee, tea, cola or other caffeinated beverages per day
  • Patient is a regular use (including "recreational use") of any illicit drugs, has a positive urine drug screen before randomization or has a history of drug (including alcohol) abuse within approximately the past 2 years
  • Patient has prior exposure to MK 0752 with the past 21 days

研究组 & 干预措施

A

Active Comparator

MK0752 1000 mg

干预措施: MK0752 (Drug)

结局指标

主要结局

To evaluate the existing Notch response signature using plucked hair follicle profiling data from health young male volunteers given 1000 mg MK0752 and 350 mg MK0752.

时间窗: 8.5 hours post dose.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

A Clinical Study to Determine Biomarkers of Response... | 临床试验